GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (NAS:CDNA) » Definitions » Cyclically Adjusted PS Ratio

CDNA (CareDx) Cyclically Adjusted PS Ratio : 3.58 (As of May. 29, 2025)


View and export this data going back to 2014. Start your Free Trial

What is CareDx Cyclically Adjusted PS Ratio?

As of today (2025-05-29), CareDx's current share price is $16.56. CareDx's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $4.62. CareDx's Cyclically Adjusted PS Ratio for today is 3.58.

The historical rank and industry rank for CareDx's Cyclically Adjusted PS Ratio or its related term are showing as below:

CDNA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.22   Med: 3.32   Max: 7.57
Current: 3.7

During the past years, CareDx's highest Cyclically Adjusted PS Ratio was 7.57. The lowest was 1.22. And the median was 3.32.

CDNA's Cyclically Adjusted PS Ratio is ranked worse than
66.67% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06 vs CDNA: 3.70

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CareDx's adjusted revenue per share data for the three months ended in Mar. 2025 was $1.532. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $4.62 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


CareDx Cyclically Adjusted PS Ratio Historical Data

The historical data trend for CareDx's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx Cyclically Adjusted PS Ratio Chart

CareDx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.97 2.93 4.77

CareDx Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.50 3.56 7.01 4.77 3.84

Competitive Comparison of CareDx's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, CareDx's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CareDx's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CareDx's Cyclically Adjusted PS Ratio falls into.


;
;

CareDx Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

CareDx's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=16.56/4.62
=3.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CareDx's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, CareDx's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.532/134.9266*134.9266
=1.532

Current CPI (Mar. 2025) = 134.9266.

CareDx Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.602 100.684 0.807
201509 0.601 100.392 0.808
201512 0.559 99.792 0.756
201603 0.548 100.470 0.736
201606 0.791 101.688 1.050
201609 0.640 101.861 0.848
201612 0.510 101.863 0.676
201703 0.543 102.862 0.712
201706 0.563 103.349 0.735
201709 0.541 104.136 0.701
201712 0.446 104.011 0.579
201803 0.475 105.290 0.609
201806 0.501 106.317 0.636
201809 0.570 106.507 0.722
201812 0.585 105.998 0.745
201903 0.624 107.251 0.785
201906 0.747 108.070 0.933
201909 0.798 108.329 0.994
201912 0.844 108.420 1.050
202003 0.896 108.902 1.110
202006 0.935 108.767 1.160
202009 1.089 109.815 1.338
202012 1.188 109.897 1.459
202103 1.317 111.754 1.590
202106 1.421 114.631 1.673
202109 1.435 115.734 1.673
202112 1.499 117.630 1.719
202203 1.498 121.301 1.666
202206 1.514 125.017 1.634
202209 1.484 125.227 1.599
202212 1.539 125.222 1.658
202303 1.440 127.348 1.526
202306 1.306 128.729 1.369
202309 1.240 129.860 1.288
202312 1.228 129.419 1.280
202403 1.394 131.776 1.427
202406 1.768 132.554 1.800
202409 1.567 133.029 1.589
202412 1.242 133.157 1.259
202503 1.532 134.927 1.532

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CareDx  (NAS:CDNA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


CareDx Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of CareDx's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CareDx Business Description

Traded in Other Exchanges
Address
8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Executives
Christine Cournoyer director 150 SHAW ROAD, CHESTNUT MA 02467
Peter Maag director, officer: President and CEO CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abhishek Jain officer: See Remarks C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Alexander L Johnson officer: Chief Business Officer C/O DIADEXUS, INC., 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Reginald Seeto officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Abraham Ronai officer: See Remarks C/O CAREDX, INC., 8000 MARINA BLVD, BRISBANE CA 94005
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Michael Goldberg director 3000 SAND HILL ROAD, BUILDING 3, SUITE 290, MENLO PARK CA 94025
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Arthur A Torres director 87 BVENA VISTA TERRACE, SAN FRANCISCO CA 94117
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Sasha King officer: Chief Commercial Officer C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
William A Hagstrom director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ralph Snyderman director C/O SAIC, 10260 CAMPUS POINT DR M/S F3, SAN DIEGO CA 92121